figure 3 The spherical region of interest (green circles) superimposed on the 18 F-dopa positron-emission tomography (pet) and contrastenhanced magnetic resonance imaging (mri) images for patients 1-3 at baseline and follow-up. Baseline images were acquired before tumour resection (left side of image pairs) and at 4 weeks after chemoradiation therapy (right side if image pairs
Early prediction of treatment response in advanced gliomas with 18 F-dopa positron-emission tomography chemoradiotherapy (external-beam radiotherapy of 60 Gy in 30 fractions or 40 Gy in 15 fractions, with concurrent temozolomide), and 4 weeks' recovery to minimize potential treatment-induced variations in metabolism. (Figure 1 provides a schematic outline.) The pet intensities were normalized to the ipsilateral cerebellum and reported as standardized uptake value ratios. One patient did not receive chemoradiotherapy.
After rigid registration, the most metabolically active voxel in each post-treatment tumour was selected from the pet image. Using nearby anatomic features from the fused mri, the corresponding location was selected on the pre-surgery image under the guidance of experienced specialists (PT, MF, RLJ, CW, AC) blinded to the pre-treatment pet image and patient outcome. The mean 18 F-dopa uptake within a 1-cm radius sphere centred on each landmark was calculated before computing the difference between baseline and follow-up. The 1-cm radius traded off the typical statistical variation in pet intensities and potential inaccuracies in spatial correspondences with the size of metabolically active regions. A Cox proportional hazards analysis model was used to evaluate the relationship between variations in 18 Fdopa uptake and survival.
Survival times, plotted in Figure 2 as a function of change in 18 F-dopa uptake, ranged from less than 30 weeks to more than 110 weeks. At last report, 3 patients remained alive. Variations in 18 F-dopa uptake ranged from less than -50% to more than +20%. The results, summarized in Table ii, demonstrate that a decrease in 18 F-dopa uptake is a predictor of extended survival. For interest, the selected regions in each patient are shown in Figures 3-5 . A Cox proportional hazards model fitted the data closely (r = 0.65), and showed that the hazard to the patient declined by 10.3% with each 1% decrease in local 18 F-dopa uptake. The null hypothesis-that changes in 18 F-dopa are not related to survival-was rejected with some significance (p < 0.032).
A second model, incorporating age and sex, was compared with the first using analysis of variance
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Imaging markers that enable prediction of survival are of interest for aiding clinical decision-making for patients with advanced glioma. However, current imaging methods based on the use of contrastenhanced magnetic resonance imaging (mri) and 18 F-fludeoxyglucose positron-emission tomography (pet) applied in the early stages after treatment are not strongly correlated with patient outcome. In conjunction with mri, amino-acid pet tracers have shown promise for this application, including variations in l-[methyl-11 C]-methionine uptake 1 and 3′-dexoy-3′-[ 18 F] fluorothymidine (flt) 2 uptake, and volume variations of regions with high flt and 6-[ 18 F] fluoro-l-dopa ( 18 F-dopa) 3 uptake.
Uptake of flt is predictive of survival in recurrent advanced glioma, even when chemotherapy renders mri unreliable 2 . However, previous serial assessments have typically considered global uptake within the tumour 1,2,4 , even though treatment failure frequently occurs locally within areas of existing abnormality 5 .
The hypothesis explored here is that poor patient survival is directly related to the extent of the most treatment-resistant cluster of malignant cells exhibiting persistent metabolic activity. Apart from the use of 18 F-dopa as an early surrogate marker, a key difference between this study and previous work is the longitudinal comparison of metabolic activity within focal peritumoural regions.
The study enrolled 9 patients (7 men; age range: 52-71 years), summarized in Table i , with histopathologically confirmed high-grade brain tumour (World Health Organization grade iv). The institutional ethics review board approved the study, and patients provided informed written consent. Patients received mri and 18 F-dopa pet scans at two time points: a baseline immediately before tumour resection, and a follow-up at 12 weeks after resection. The post-resection interval consisted of 2 weeks' recovery, a 6-week course of ( Table iii) . The comparison showed that the models largely overlapped ( p > 0.7), and consecutive increases for log likelihood (4.74 for change in local 18 F-dopa, 0.24 for age, and 0.23 for sex) indicated that age and sex had a more limited influence on the results. Finally, global 18 F-dopa uptake (mean over the entire tumour) was compared with survival. Compared with local 18 F-dopa, global 18 F-dopa was less correlated with survival (5.2% decline in hazard for 1% decrease in uptake), had a poorer fit (r = 0.33), and was less significant (p < 0.1). 
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